Cougar Biotechnology's IPO

Cougar Biotechnology raised a round of funding on February 21, 2007. Investors include Public.

Cougar Biotechnology aims to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trial…

Articles about Cougar Biotechnology's IPO: